Adaptive Biotechnologies Corp (NAS:ADPT)
$ 6.13 -0.25 (-3.92%) Market Cap: 941.56 Mil Enterprise Value: 838.75 Mil PE Ratio: 0 PB Ratio: 4.20 GF Score: 81/100

Adaptive Biotechnologies Corp at UBS Genomics 2.0 and Medtech Innovations Summit (Virtual) Transcript

Aug 11, 2020 / 06:00PM GMT
Release Date Price: $36.78 (-2.18%)
Daniel Gregory Brennan
UBS Investment Bank, Research Division - Senior Equity Research Analyst of Healthcare Life Sciences

Good afternoon. Welcome to another session here, day 1 of the UBS Genomics 2.0 Medtech Summit -- Medtech Innovations Summit, excuse me. Really pleased to be joined with me here at 2:00 session with Chad Robins, CEO, Co-Founder of Adaptive Biotechnologies. Chad has been amazing through this conference. I met Chad, I don't know, 6 or 7 years ago when John was hosting this conference, when he was at Macquarie. And since then I've followed the company. Obviously done remarkably well quarter last night, which we'll get into. And Chad has been super impactful as a -- kind of helped orchestrate this conference, making a lot of introductions. So beyond the scenes, he's been absolutely fantastic.

So Chad, thank you for all your help and support on the conference, and welcome.

Chad M. Robins
Adaptive Biotechnologies Corporation - Co-Founder, CEO & Chairman

Thanks, Dan. It's great to be here. Appreciate it.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot